{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:41:28Z","timestamp":1792536088981,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00213-015-3891-4","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:49:24Z","timestamp":1426034964000},"page":"2597-2607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients"],"prefix":"10.1007","volume":"232","author":[{"given":"Eline R.","family":"Zaaijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kora","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Goudriaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureen A.","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten W. J.","family":"Koeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Booij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"3891_CR1","doi-asserted-by":"crossref","unstructured":"Arnou RC, Meagher MW, Norris MP, Bramson R (2001) Psychometric evaluation of the beck depression inventory-II with primary care medical patients. Health Psychol 20:112\u2013119","DOI":"10.1037\/0278-6133.20.2.112"},{"key":"3891_CR2","doi-asserted-by":"crossref","unstructured":"Bergstrom K, Jolkkonen J, Kuikka JT, Akerman KK, Viinamaki H, Airaksinen O, Lansimies E, Tiihonen J (1998) Fentanyl decreases \u03b2-CIT binding to the dopamine transporter. Synapse 29:413\u2013415","DOI":"10.1002\/(SICI)1098-2396(199808)29:4<413::AID-SYN13>3.0.CO;2-R"},{"key":"3891_CR3","doi-asserted-by":"crossref","unstructured":"Bhargava HN, Gudehithlu KP (1996) Chronic blockade of opioid receptors alters the binding of [3H]GBR 12935 to dopamine transporter in rat brain regions and spinal cord. Pharmacology 52:243\u2013251","DOI":"10.1159\/000139389"},{"key":"3891_CR4","doi-asserted-by":"crossref","unstructured":"Booij J, Kemp P (2008) Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 35:424\u2013438","DOI":"10.1007\/s00259-007-0621-0"},{"key":"3891_CR5","doi-asserted-by":"crossref","unstructured":"Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AGM, Wolters ECH (1997) [123I] FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson \u2019s disease. J Neurol Neurosurg Psychiatry 62:133\u2013140","DOI":"10.1136\/jnnp.62.2.133"},{"key":"3891_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002590050374","volume":"26","author":"J Booij","year":"1999","unstructured":"Booij J, Tissingh G, Winogrodzka A, van Royen EA (1999) Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26:171\u2013182","journal-title":"Eur J Nucl Med"},{"key":"3891_CR7","doi-asserted-by":"crossref","unstructured":"Boot E, Booij J, Hasler G, Zinkstok JR, de Haan L, Linszen DH, van Amelsvoort TA (2008) AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging 35:1350\u20131356","DOI":"10.1007\/s00259-008-0739-8"},{"key":"3891_CR8","volume-title":"Statistical power analysis for the behavioral sciences (rev. ed.)","author":"J Cohen","year":"1977","unstructured":"Cohen J (1977) Statistical power analysis for the behavioral sciences (rev. ed.). Lawrence Erlbaum Associates, Inc, Hillsdale"},{"key":"3891_CR9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pscychresns.2010.08.001","volume":"184","author":"KP Cosgrove","year":"2010","unstructured":"Cosgrove KP, Tellez-Jacques K, Pittman B, Petrakis I, Baldwin RM, Tamagnan G, Seibyl J, Kosten T, Staley JK (2010) Dopamine and serotonin transporter availability in chronic heroin users: a [123I]\u03b2-CIT SPECT imaging study. Psychiatry Res 184:192\u2013195","journal-title":"Psychiatry Res"},{"key":"3891_CR10","unstructured":"Cruts G, van Laar M, Buster M (2013) Aantal en kenmerken van problematische opiatengebruikers in Nederland"},{"key":"3891_CR11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/bjsm.26.2.111","volume":"26","author":"M Daniel","year":"1992","unstructured":"Daniel M, Martin AD, Carter J (1992) Opiate receptor blockade by naltrexone and mood state after acute physical activity. Br J Sports Med 26:111\u2013115","journal-title":"Br J Sports Med"},{"key":"3891_CR12","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/syn.20914","volume":"65","author":"K Danielson","year":"2011","unstructured":"Danielson K, Truman P, Kivell BM (2011) The effects of nicotine and cigarette smoke on the monoamine transporters. Synapse 65:866\u2013879","journal-title":"Synapse"},{"key":"3891_CR13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clineuro.2007.08.007","volume":"110","author":"R David","year":"2008","unstructured":"David R, Koulibaly M, Benoit M, Garcia R, Caci H, Darcourt J, Robert P (2008) Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction. Clin Neurol Neurosurg 110:19\u201324","journal-title":"Clin Neurol Neurosurg"},{"key":"3891_CR14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/sj.npp.1300683","volume":"30","author":"MML Win De","year":"2005","unstructured":"De Win MML, Habraken JBA, Reneman L, van den Brink W, den Heeten GJ, Booij J (2005) Validation of [123I]\u03b2-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 30:996\u20131005","journal-title":"Neuropsychopharmacology"},{"key":"3891_CR15","first-page":"38","volume":"31","author":"AJ Dean","year":"2006","unstructured":"Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR (2006) Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci 31:38\u201345","journal-title":"J Psychiatry Neurosci"},{"key":"3891_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/dar.12088","volume":"33","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, Whiteford H, Hall WD (2014) The Global Burden of Disease projects: what have we learned about illicit drug use and dependence and their contribution to the global burden of disease? Drug Alcohol Rev 33:4\u201312","journal-title":"Drug Alcohol Rev"},{"key":"3891_CR17","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","volume":"85","author":"G Chiara Di","year":"1988","unstructured":"Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274\u20135278","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3891_CR18","unstructured":"EMCDDA (2013) European Drug Report"},{"key":"3891_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2006.08.020","volume":"99","author":"IHA Franken","year":"2007","unstructured":"Franken IHA, Rassin E, Muris P (2007) The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord 99:83\u201389","journal-title":"J Affect Disord"},{"key":"3891_CR20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.2010.05900.x","volume":"1216","author":"DR Gastfriend","year":"2011","unstructured":"Gastfriend DR (2011) Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci 1216:144\u2013166","journal-title":"Ann N Y Acad Sci"},{"key":"3891_CR21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstr\u00f6m KO (1991) The Fagerstr\u00f6m test for nicotine dependence: a revision of the Fagerstr\u00f6m tolerance questionnaire. Br J Addict 86:1119\u20131127","journal-title":"Br J Addict"},{"key":"3891_CR22","doi-asserted-by":"crossref","unstructured":"Hollister LE, Johnson K, Boukhabza D, Gillespie HK (1981) Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 8:37\u201341","DOI":"10.1016\/0376-8716(81)90084-3"},{"key":"3891_CR23","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn R et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533\u20131539","journal-title":"J Cereb Blood Flow Metab"},{"key":"3891_CR24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/13556210500222456","volume":"10","author":"SW Jia","year":"2005","unstructured":"Jia SW, Wang W, Liu Y, Wu ZM (2005) Neuroimaging studies of brain corpus striatum changes among heroin-dependent patients treated with herbal medicine, U\u2019finer capsule. Addict Biol 10:293\u2013297","journal-title":"Addict Biol"},{"key":"3891_CR25","first-page":"906","volume":"21","author":"AC King","year":"1997","unstructured":"King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ (1997) Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 21:906\u2013909","journal-title":"Alcohol Clin Exp Res"},{"key":"3891_CR26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0893-133X(00)00209-8","volume":"24","author":"SJ Kish","year":"2001","unstructured":"Kish SJ, Kalasinsky KS, Derkach P, Schmunck GA, Guttman M, Ang L, Adams V, Furukawa Y, Haycock JW (2001) Striatal dopaminergic and serotonergic markers in human heroin users. Neuropsychopharmacology 24:561\u2013567","journal-title":"Neuropsychopharmacology"},{"key":"3891_CR27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.psych.59.103006.093548","volume":"59","author":"GF Koob","year":"2008","unstructured":"Koob GF, Le Moal M (2008) Addiction and the brain antireward system. Annu Rev Psychol 59:29\u201353","journal-title":"Annu Rev Psychol"},{"key":"3891_CR28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/YCO.0b013e3283386578","volume":"23","author":"EM Krupitsky","year":"2010","unstructured":"Krupitsky EM, Blokhina EA (2010) Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry 23:210\u2013214","journal-title":"Curr Opin Psychiatry"},{"key":"3891_CR29","author":"C-S Liang","year":"2014","unstructured":"Liang C-S, Ho P-S, Yen C-H, Yeh Y-W, Kuo S-C, Huang C-C, Chen C-Y, Shih M-C, Ma K-H, Huang S-Y (2014) Reduced striatal dopamine transporter density associated with working memory deficits in opioid-dependent male subjects: a SPECT study. Addict Biol. doi: 10.1111\/adb.12203","journal-title":"Addict Biol"},{"key":"3891_CR30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00213-013-3148-z","volume":"230","author":"Y Liu","year":"2013","unstructured":"Liu Y, Han M, Liu X, Deng Y, Li Y, Yuan J, Lv R, Wang Y, Zhang G, Gao J (2013) Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment. Psychopharmacology (Berl) 230:235\u2013244","journal-title":"Psychopharmacology (Berl)"},{"key":"3891_CR31","first-page":"CD006140","volume":"16","author":"P Lobmaier","year":"2008","unstructured":"Lobmaier P, Kornor H, Kunoe N, Bj\u00f8rndal A (2008) Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 16:CD006140","journal-title":"Cochrane Database Syst Rev"},{"key":"3891_CR32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1755-5949.2010.00194.x","volume":"17","author":"PP Lobmaier","year":"2011","unstructured":"Lobmaier PP, Kun\u00f8e N, Gossop M, Waal H (2011) Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther 17:629\u2013636","journal-title":"CNS Neurosci Ther"},{"key":"3891_CR33","first-page":"CD001333","volume":"16","author":"S Minozzi","year":"2011","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (2011) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 16:CD001333","journal-title":"Cochrane Database Syst Rev"},{"key":"3891_CR34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10550490290087929","volume":"11","author":"K Miotto","year":"2002","unstructured":"Miotto K, Mccann M, Basch J, Rawson R, Ling W (2002) Naltrexone and dysphoria : fact or myth ? Am J Addict 11:151\u2013160","journal-title":"Am J Addict"},{"key":"3891_CR35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1210\/jcem-71-4-1056","volume":"71","author":"MR Murphy","year":"1990","unstructured":"Murphy MR, Checkley SA, Seckl JR, Lightman SL (1990) Naloxone inhibits oxytocin release at orgasm in man. J Clin Endocrinol Metab 71:1056\u20131058","journal-title":"J Clin Endocrinol Metab"},{"key":"3891_CR36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00952990.2010.540281","volume":"37","author":"DJ Mysels","year":"2011","unstructured":"Mysels DJ, Cheng WY, Nunes EV, Sullivan MA (2011) The association between naltrexone treatment and symptoms of depression in opioid dependent patients. Am J Drug Alcohol Abuse 37:22\u201326","journal-title":"Am J Drug Alcohol Abuse"},{"key":"3891_CR37","unstructured":"NDM (2012) National Drug Monitor Annual Report"},{"key":"3891_CR38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.drugalcdep.2012.06.030","volume":"127","author":"J Neale","year":"2013","unstructured":"Neale J, Nettleton S, Pickering L (2013) Does recovery-oriented treatment prompt heroin users prematurely into detoxification and abstinence programmes? Qualitative study. Drug Alcohol Depend 127:163\u2013169","journal-title":"Drug Alcohol Depend"},{"key":"3891_CR39","first-page":"106","volume":"20","author":"CP O\u2019Brien","year":"2010","unstructured":"O\u2019Brien CP, Gastfriend DR, Forman RF, Schweizer E, Pettinati HM (2010) Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone. Am J Addict 20:106\u2013112","journal-title":"Am J Addict"},{"key":"3891_CR40","doi-asserted-by":"crossref","unstructured":"Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T (1993) Pharmacological characterization of the cloned \u03ba-, \u03b4-, and \u03bc-opioid receptors. Mol Pharmacol 45:330\u2013334","DOI":"10.1016\/S0026-895X(25)09932-8"},{"key":"3891_CR41","doi-asserted-by":"crossref","unstructured":"Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, Ferrannini E, Tartaglione B, Defazio G, Rubini G, Livrea P (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 24:2097\u20132103","DOI":"10.1002\/mds.22702"},{"key":"3891_CR42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pscychresns.2006.03.001","volume":"147","author":"M Sarchiapone","year":"2006","unstructured":"Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, Focacci C, De Risio S (2006) Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 147:243\u2013248","journal-title":"Psychiatry Res"},{"key":"3891_CR43","first-page":"15","volume":"22","author":"B Schmand","year":"1991","unstructured":"Schmand B, Bakker D, Saan R, Louman J (1991) The Dutch Reading Test for Adults: a measure of premorbid intelligence level. Tijdschr Gerontol Geriatr 22:15\u201319","journal-title":"Tijdschr Gerontol Geriatr"},{"key":"3891_CR44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1749-6632.2009.05148.x","volume":"1187","author":"KC Schmitt","year":"2010","unstructured":"Schmitt KC, Reith MEA (2010) Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann NY Acad Sci 1187:316\u2013340","journal-title":"Ann NY Acad Sci"},{"key":"3891_CR45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.09.042","volume":"579","author":"J Shi","year":"2008","unstructured":"Shi J, Zhao L-Y, Copersino ML, Fang Y-X, Chen Y, Tian J, Deng Y, Shuai Y, Jin J, Lu L (2008) PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol 579:160\u2013166","journal-title":"Eur J Pharmacol"},{"key":"3891_CR46","doi-asserted-by":"crossref","unstructured":"Slawson MH, Chen M, Moody D, Comer SD, Nuwayser ES, Fang WB, Foltz RL (2007) Quantitative analysis of naltrexone and 6\u03b2-naltrexol in human, rat, and rabbit plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with application to the pharmacokinetics of Depotrex in rabbits. J Anal Toxicol 31:453\u2013461","DOI":"10.1093\/jat\/31.8.453"},{"key":"3891_CR47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.167.1.99","volume":"167","author":"RP Snaith","year":"1995","unstructured":"Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P (1995) A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 167:99\u2013103","journal-title":"Br J Psychiatry"},{"key":"3891_CR48","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","volume":"27","author":"YY Syed","year":"2013","unstructured":"Syed YY, Keating GM (2013) Extended-release intramuscular naltrexone (VIVITROL\u00ae): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs 27:851\u2013861","journal-title":"CNS Drugs"},{"key":"3891_CR49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s004150050168","volume":"245","author":"G Tissingh","year":"1998","unstructured":"Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA (1998) Drug-naive patients with Parkinson \u2019s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]\u03b2-CIT SPECT. J Neurol 245:14\u201320","journal-title":"J Neurol"},{"key":"3891_CR50","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/S0924-977X(11)70213-9","volume":"21","author":"A Tiurina","year":"2011","unstructured":"Tiurina A, Krupitsky E, Blokhina E, Bushara N, Palatkin V, Zvartay E, Burakov A, Masalov D, Verbitskaya E, Woody G (2011) Analysis of the impact of different forms of naltrexone on the syndrome of anhedonia and depression among heroin addicts. Eur Neuropsychopharmacol 21:S166","journal-title":"Eur Neuropsychopharmacol"},{"key":"3891_CR51","unstructured":"UNODC (2012) World drug report 2012. New York"},{"key":"3891_CR52","unstructured":"Van Vliet IM, De Beurs E (2007) Het mini internationaal neuropsychiatrisch interview (MINI) Een kort gestructureerd diagnostisch psychiatrisch interview voor. Tijdschr Psychiatr 49:393\u2013397"},{"issue":"9","key":"3891_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2013.07.005","volume":"34","author":"RA Vaughan","year":"2013","unstructured":"Vaughan RA, Foster JD (2013) Mechanism of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci 34(9):1\u201316","journal-title":"Trends Pharmacol Sci"},{"key":"3891_CR54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/syn.890210207","volume":"21","author":"RA Wise","year":"1995","unstructured":"Wise RA, Leone P, Rivest R, Leeb K (1995) Elevations of nucleus accumbens dopamine and DOPAC levels during intravenous heroin self-administration. Synapse 21:140\u2013148","journal-title":"Synapse"},{"key":"3891_CR55","unstructured":"Wisselink DJ, Kuijpers WGT, Mol A (2013) Kerncijfers Verslavingszorg 2013 Landelijk Alcohol en Drugs Informatie Systeem ( LADIS)"},{"key":"3891_CR56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00213-011-2454-6","volume":"220","author":"TL Yeh","year":"2012","unstructured":"Yeh TL, Chen KC, Lin S-H, Lee IH, Chen PS, Yao WJ, Lee S-Y, Yang Y-K, Lu R-B, Liao M-H, Chiu N-T (2012) Availability of dopamine and serotonin transporters in opioid-dependent users\u2013a two-isotope SPECT study. Psychopharmacology (Berl) 220:55\u201364","journal-title":"Psychopharmacology (Berl)"},{"key":"3891_CR57","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0149-7634(02)00041-6","volume":"26","author":"MR Yeomans","year":"2002","unstructured":"Yeomans MR, Gray RW (2002) Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 26:713\u2013728","journal-title":"Neurosci Biobehav Rev"},{"key":"3891_CR58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1355621961000124666","volume":"1","author":"L Yu","year":"1996","unstructured":"Yu L (1996) The mu opioid receptor: from molecular cloning to functional studies. Addict Biol 1:19\u201330","journal-title":"Addict Biol"},{"key":"3891_CR59","doi-asserted-by":"crossref","unstructured":"Zaaijer ER, de Bruin K, la Fleur SE, Goudriaan AE, van den Brink W, Booij J (2015) Subchronic administration of short acting naltrexone has no effect on striatal dopamine transporter availability, food intake or body weight gain in rats. J. Psychopharmacol. doi: 10.1177\/0269881114565380","DOI":"10.1177\/0269881114565380"},{"key":"3891_CR60","doi-asserted-by":"crossref","unstructured":"Zijlstra F, Booij J, van den Brink W, Franken IHA (2008) Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol 18:262\u2013270","DOI":"10.1016\/j.euroneuro.2007.11.002"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-015-3891-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-015-3891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-015-3891-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T21:06:05Z","timestamp":1747775165000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-015-3891-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":60,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["3891"],"URL":"https:\/\/doi.org\/10.1007\/s00213-015-3891-4","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]}}}